[Age and pathological features of 481 prostate cancer patients].

Liping Xie(First Affiliated Hospital Zhejiang University), Xinru Yu(Ningbo University), Wei Ding(Shanghai Ninth People's Hospital), Zhigen Zhang(Zhejiang University), Lijun Wang(Beijing Tsinghua Chang Gung Hospital), Jie Qin, Guoping Ren(Queen Mary University of London), Huafeng Shen(First Affiliated Hospital Zhejiang University), Zhao-Dian Chen, Song-Liang Cai, Xiangyi Zheng(Tianjin University)
PubMed
June 1, 2005
Cited by 8

Related Papers

The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276
Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels
|Oncotarget|2017|207
Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells <i>in vitro</i> and inhibits tumor growth <i>in vivo</i>
|Cancer Science|2009|188